Baricitinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Aicardi Goutieres Syndrome

Conditions

Aicardi Goutieres Syndrome

Trial Timeline

Jun 3, 2019 → Mar 25, 2024

NCT ID

NCT03921554

About Baricitinib

Baricitinib is a phase 2 stage product being developed by Eli Lilly for Aicardi Goutieres Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT03921554. Target conditions include Aicardi Goutieres Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01724580	Pre-clinical	Completed	—	—	Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
NCT06797310	Phase 2	Recruiting	Jan 23, 2025	Dec 31, 2026	Alopecia Areata
NCT05074420	Phase 3	Terminated	Dec 21, 2021	Nov 4, 2024	Covid19
NCT04517253	Phase 2/3	Terminated	Oct 27, 2020	Nov 28, 2024	Nakajo-Nishimura Syndrome
NCT03921554	Phase 2	Completed	Jun 3, 2019	Mar 25, 2024	Aicardi Goutieres Syndrome
NCT03773965	Phase 3	Recruiting	Apr 5, 2019	Jul 1, 2031	Juvenile Idiopathic Arthritis
NCT03559270	Phase 3	Terminated	Jun 27, 2018	Jun 13, 2022	Atopic Dermatitis
NCT03026504	Phase 2	Completed	Mar 9, 2017	Apr 12, 2021	Arteritis, Giant Cell
NCT02263911	Phase 1	Completed	Nov 1, 2014	Dec 1, 2014	Healthy Participants
NCT01870388	Phase 1	Completed	Jun 1, 2013	Jul 1, 2013	Liver Diseases

Competing Products

1 competing product in Aicardi Goutieres Syndrome

See all competitors

Product	Company	Stage	Hype Score
Tenofovir (TDF) and Emtricitabine (FTC)	Gilead Sciences	Phase 1/2	40

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved